Genmab A/S (GMAB) has a consensus analyst rating of Buy, based on 17 analysts covering the stock. Of those, 12 recommend buying, 4 recommend holding, and 1 recommend selling.
The analyst consensus price target for GMAB is $42.13, representing a +45.0% upside from the current price of $29.06. Price targets range from a low of $39.00 to a high of $48.00.
